Reby Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Reby Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$25K	Buy	+177	New	+$22.7K	0.01%	327

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Reby Advisors's XBI Position: Q4 2020 in Review

Reby Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2020: 177 shares worth $25K. The stake represents 0.01% of the portfolio and ranks #327 among its holdings.

654 funds tracked by Wall St. Rank hold XBI as of Q4 2020.

Reby Advisors held 177 shares of State Street SPDR S&P Biotech ETF worth $25K as of Q4 2020.
State Street SPDR S&P Biotech ETF was a new Reby Advisors position in Q4 2020.
State Street SPDR S&P Biotech ETF made up 0.01% of Reby Advisors's portfolio in Q4 2020, its #327 holding.
654 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.